Close Menu

BARCELONA – In presentations at the annual meeting of the European Society for Medical Oncology in Barcelona on Friday, researchers reported seemingly contradictory results on the utility of tumor mutational burden (TMB) as a biomarker for treatment of advanced non-small cell lung cancer (NSCLC) with pembrolizumab (Merck's Keytruda).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.